Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. hemostasis
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Hemostasis Articles & Analysis

29 news found

The Use of Infrared Coagulation in Hair Transplant and Scalp Reduction Surgery

The Use of Infrared Coagulation in Hair Transplant and Scalp Reduction Surgery

The infrared coagulator with its multiple-sized tips and pinpoint accuracy has proven to be superior (especially in a wet field) in providing excellent hemostasis, allowing minimal blood loss, and in allowing the clearest visual field in pe,forming both hair transplant and scalp reduction surgery. ...

ByRedfield Corporation


Point of Care System for Blood Coagulation Monitoring

Point of Care System for Blood Coagulation Monitoring

(PRWEB) January 19, 2018 — Entegrion, Inc. today announced that it has achieved CE mark for the Company’s portable coagulation monitoring system (“PCM”) for use in clinical settings for the viscoelastic measurement of patient whole blood coagulation and hemostasis. The CE marking signifies Entegrion’s declaration that the PCM complies with the ...

ByEntegrion, Inc.


Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian

Factor XI is a promising and differentiated target for the development of safer anticoagulants because of its critical role in pathological versus normal thrombus formation uncoupling hemostasis from thrombosis. Patients with congenital Factor XI genetic deficiency demonstrate a lower risk for venous thromboembolism and ischemic stroke but rarely have spontaneous bleeding.1 The ...

ByBayer AG


Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models

Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models

Gandras et al. evaluated[i] the ability of Embrace HES to achieve hemostasis in a porcine mesenteric artery hemorrhage model that replicates injury in humans. ...

ByInstylla, Inc.


The next evolution in blood vessel occlusion

The next evolution in blood vessel occlusion

Little medical innovation occurred during the fifth to 15th centuries where the standard for wound hemostasis was cautery. Bleeding wounds and vessels were commonly burnt with heated oils. ...

ByAmsel Medical Corporation


ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.

ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.

The study design will be presented at the International Society of Thrombosis and Hemostasis (ISTH) Congress in London, U.K in July 2022 and is available at https://www.clinicaltrials.gov/ct2/show/NCT04676048. ...

ByASC Therapeutics


Stago introduces a new flow analysis service: MyOptiLab

Stago introduces a new flow analysis service: MyOptiLab

The new MyOptiLab workflow analysis service is part of a broader strategy aimed at working more closely with laboratories. It is an elaborate process designed to optimise organisational excellence. Workflow analysis might be described as an unbiased, real-time observation of business processes in place. It identifies causes of inefficiency and areas for improvement. MyOptiLab carries out ...

ByDiagnostica Stago S.A.S.


Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

” “From vessel injury to failure of obtaining hemostasis with access closure devices, bleeding complications in interventional procedures continue to pose challenges for clinicians,” said Dr. ...

BySaranas, Inc.


Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors

Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors

Her expertise focuses on therapeutic areas of cardiovascular disease (thrombosis, hemostasis, atherosclerosis, coagulation, hyperlipidemia), inflammation, autoimmune diseases, and hematologic malignancies. ...

ByCellphire Therapeutics, Inc.


World Thrombosis Day

World Thrombosis Day

On World Thrombosis Day, October 13, 2021, Emosis is proud to be a "messenger" of the "Eyes open to Thrombosis" information campaign. Eyes open to Thrombosis WTD is an educational campaign to raise awareness and educate the public to the importance of reducing death and disability from thrombosis. It is a global alliance of thousands of local, regional, national and international ...

ByEmosis Diagnostics SAS


CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

Michael Gibson and an Executive Committee comprised of world–renowned cardiac surgeons, interventional cardiologists, and thrombosis/hemostasis experts. Trial start-up activities are underway and we expect the study to start in the first quarter of ...

ByCytoSorbents Corporation


Abram Scientific Secures $1 Million National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II Grant

Abram Scientific Secures $1 Million National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II Grant

Abram’s CoagCare System is a novel diagnostic platform for diagnosis and characterization of coagulation-related disorders, delivering rapid hemostasis information to improve clinical outcomes. The CoagCare System is designed as a point-of-care (POC) meter and single-use diagnostic test card. ...

ByAbram Scientific, Inc.


Abram Scientific Secures $2.9 Million US Army Medical Research Grant to Deliver a Portable Viscoelastic, Blood Coagulation Diagnostic Platform for COVID-19 associated Coagulopathy Management

Abram Scientific Secures $2.9 Million US Army Medical Research Grant to Deliver a Portable Viscoelastic, Blood Coagulation Diagnostic Platform for COVID-19 associated Coagulopathy Management

Abram’s CoagCare System is a novel diagnostic platform for diagnosis and characterization of coagulation-related disorders, delivering rapid hemostasis information to improve clinical outcomes. The CoagCare System is designed as a point-of-care (POC) meter and single-use diagnostic test card. ...

ByAbram Scientific, Inc.


TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

TISSIUM’s vascular sealant is designed to address the issue of quickly achieving hemostasis and preventing post-operative bleeding following peripheral vascular surgeries, while also offering biocompatibility and a simple preparation and application process for surgeons. ...

ByTISSIUM


GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

A selective small molecule targeting a key anticoagulant is a promising and novel approach to restore normal hemostasis and provides a far more convenient therapeutic option for hemophilia patients. ...

ByAtomwise Inc.


USPTO issues Patent for ground breaking polysaccharide technology platform to Endomedix.

USPTO issues Patent for ground breaking polysaccharide technology platform to Endomedix.

The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. ...

ByEndomedix, Inc.


Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million

Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million

As such, it is important to highlight the FDA approvals of QNext®, a coagulometer developed in-house, and DG-PT (thromboplastin), one of the main reagents to promote hemostasis. With this latter approval, Grifols became the first company in more than 15 years to earn authorization in the U.S. market to sell instruments and reagents for routine hemostasis ...

ByGrifols International, S.A.


Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder

Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder

Made with HDBRAID technology, the LOBO occluder provides a dense pore structure that spans the vessel lumen to rapidly reduce flow and accelerate hemostasis. The multiple-disk design compounds the occlusive effects of the HDBRAID technology, creating a scaffold for efficient treatment. ...

ByOkami Medical


Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical Electrophysiology

Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical Electrophysiology

Vascade MVP Indications EU: VASCADE MVP is indicated for percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time-to-discharge eligibility compared to manual compression in patients who have undergone catheter-based procedures utilizing 6-12 Fr inner diameter procedural sheaths, with single- ...

ByCardival Medical, Inc.


Endomedix, Inc. to present its innovative technology addressing the needs of Warfighters at the upcoming Military Health System and Research Symposium 2019 annual meeting

Endomedix, Inc. to present its innovative technology addressing the needs of Warfighters at the upcoming Military Health System and Research Symposium 2019 annual meeting

The poster will feature the biopolymer technology’s 5 complementary mechanisms of action that lead to fast hemostasis of heavy bleeds. 4 of the 5 complementary mechanisms are unique and the subject of the company’s latest patent applications. ...

ByEndomedix, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT